Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Clinical Trial ID NCT00129740

Rank	Title	Journal	Year	PubWeight™‹?›
1	Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.	J Clin Oncol	2009	2.78
2	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.	Lancet Haematol	2015	2.42
3	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.	Blood	2013	1.64
4	Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.	Cancer	2015	0.78
5	Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.	Clin Lymphoma Myeloma Leuk	2015	0.77
6	A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.	Cancer	2016	0.75